All Melanoma News

7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma

At a 7.5-year follow-up, nivolumab (Opdivo)-based treatment regimens continued to display superior overall survival (OS) rates, duration of response (DOR), and health-related quality of life (HRQOL) compared with ipilimumab (Yervoy) monotherapy, according to a long-term follow-up analysis of CheckMate 067 (NCT01844505) presented during the 2022 ASCO Annual Meeting.

Perlmutter Cancer Center Medical Oncologist Leads Clinical Trial Testing Adjuvant Immunotherapy for Resected Stage 3/4 Melanoma

Half of all people with melanoma who have had the tumor surgically removed are at high risk of the cancer coming back. Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone Health’s Perlmutter Cancer Center, is leading a phase 3 clinical trial at Perlmutter Cancer Center testing adjuvant immunotherapy in people with stage 3/4 melanoma that has been surgically removed. Adjuvant therapies are used to treat people with cancer after surgery.

Novel radiopharmaceutical pair detects and treats melanoma; study shows potential for broad application in solid tumors

Vancouver, British Columbia, Canada — A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting. Targeting a receptor that is aberrantly overproduced in many human solid tumors, this theranostic (therapy + diagnostic) approach shows promise for non-invasive diagnosis and treatment of patients with various forms of cancer.

Combination drug strategy activates natural killer cell-mediated immunity to attack tumors

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function. A new study led by Penn State College of Medicine scientists finds that another type of immune cell -; natural killer cells -; can be harnessed to pick up the slack when T cells no longer work and may also reinvigorate T cells to attack melanoma tumors. The team has identified a unique combination drug strategy to activate this natural killer cell-mediated immunity in mice. The individual agents are clinically used but not in combination, and the combination still must be demonstrated to be effective in humans.

Novel drug combo activates natural killer cell immunity to destroy cancer cells

UNIVERSITY PARK, Pa. — Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function. A new study led by Penn State College of Medicine scientists finds that another type of immune cell — natural killer cells — can be harnessed to pick up the slack when T cells no longer work and may also reinvigorate T cells to attack melanoma tumors. The team has identified a unique combination drug strategy to activate this natural killer cell-mediated immunity in mice. The individual agents are clinically used but not in combination, and the combination still must be demonstrated to be effective in humans.

Omitting Node Dissection, Adjuvant Therapy May Be Safe for Some With Stage III Melanoma

Patients with resectable stage III melanoma who have a major pathologic response (MPR) to neoadjuvant therapy can skip therapeutic lymph node dissection (TLND) and adjuvant therapy — with their associated morbidity and toxicity — and still achieve high 2-year rates of relapse-free survival (RFS) and distant metastasis-free survival (DMFS), according to research presented at the 2022 ASCO Annual Meeting.

EXPERT REPORT ON NOVEL DATA IN (NEO)ADJUVANT TREATMENT OF MELANOMA FROM ASCO 2022

Reporting from ASCO 2022 Annual Meeting in Chicago, Georgina Long features the metastasis-free survival data from KEYNOTE-716 testing the benefit of adjuvant pembrolizumab vs placebo in stage IIB or IIC melanoma. She also explains the results from the NeoTrio study in resectable BRAF-mutated stage III melanoma with anti-PD1 therapy alone, in sequence with or concurrent with BRAF targeted therapy.

ASCO 2022: An Abundance of Data for the Field of Melanoma

ichael Postow, MD, offers an immediate reflection on compelling data surrounding adjuvant and neoadjuvant treatments for melanoma, as well as other items of clinical interest, presented at the ASCO 2022 conference. An update on the KEYNOTE-716 trial featured more news on the benefits of pembrolizumab in improving metastasis-free survival, and further results from the PRADO study underscored the advantages of a double round of neoadjuvant therapy.

Cobolimab Plus Dostarlimab Achieves Clinical Responses in Advanced Melanoma

Treatment with the combination of cobolimab and dostarlimab (Jemperli) led to an overall objective response rate (ORR) and immune-related ORR of 42.9% (n = 12/28) consisting of all partial responses (PRs) in patients with advanced or metastatic melanoma, according to data from the phase 1 AMBER study (NCT02817633) presented at the 2022 ASCO Annual Meeting.

Dr. Tawbi on the Safety of Relatlimab Plus Nivolumab in Melanoma

Hussein A. Tawbi, MD, PhD, director, Melanoma Clinical Research and Early Drug Development and Personalized Cancer Therapy, deputy chair and professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of relatlimab plus nivolumab (Opdualag) in patients with metastatic or unresectable melanoma, according to data from the phase 2/3 RELATIVITY-047 trial (NCT03470922).

InterVenn Biosciences Announces New Data Validating the Clinical Performance of DAWN™ IO Melanoma as a Novel Liquid Biopsy Test to Improve Assessment of Benefit to Cancer Patients

SAN FRANCISCO–(BUSINESS WIRE)–InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced new data showing that its new DAWN IO Melanoma test accurately assesses and classifies advanced melanoma patients as likely or unlikely to benefit from immune checkpoint inhibitor therapies: either pembrolizumab alone or ipilimumab in combination with nivolumab.

Adjuvant Pembrolizumab Results in Significant DMFS Improvement Over Placebo in Stage II Melanoma

Adjuvant pembrolizumab (Keytruda) was found to result in a significant improvement in distant metastasis-free survival (DMFS) compared with placebo, with a continued reduction in risk of recurrence and an acceptable safety profile in patients with resected stage IIB or stage IIC melanoma, according to data from the third interim analysis of the KEYNOTE-716 trial (NCT03553836) presented during the 2022 ASCO Annual Meeting.

Melanoma Research Alliance Announces $13 Million in Grants to Advance Melanoma Prevention, Detection & Treatment

WASHINGTON, May 19, 2022–(BUSINESS WIRE)–Coinciding with Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 27 research grants totaling $13,046,774 to support new research aimed at advancing melanoma prevention, diagnosis and treatment. Melanoma is the deadliest form of skin cancer and the fifth most common cancer in the United States.

New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors

HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) — 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”), released a new study in The Journal of Clinical Investigation, describing the use of 7HP’s novel integrin activator 7HP349 to convert “cold” or non-immunogenic tumor microenvironments to a “hot,” T cell-enriched state, improving the effectiveness of immune checkpoint blockade.

Pembrolizumab Moves Toward EU Approval for Resected Stage IIB/IIC Melanoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) for use as adjuvant therapy in adult and adolescent patients aged 12 years and older with stage IIB or IIC melanoma following complete resection. Additionally, CHMP recommended expanding the indication for pembrolizumab in advanced unresectable or metastatic and stage III melanoma as adjuvant therapy following complete resection for adolescent patients aged 12 years and older.

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC– Enrollment Stopped Early for Efficacy

EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) –Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Idera’s synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early.

Nivolumab + Relatlimab Continues Clinical Benefit in Advanced Melanoma

The combination of nivolumab and relatlimab continues to demonstrate a progression-free survival (PFS) benefit compared to nivolumab alone in patients with previously untreated metastatic or unresectable melanoma. In addition, for the first time, the dual checkpoint inhibitor therapy also demonstrated a higher overall response rate (ORR), according to follow-up data from the RELATIVITY-047 trial.

Sotigalimab/Pembrolizumab Jumpstarts Immune Activity, Ignites Clinical Responses in Metastatic Melanoma

Treatment with the CD40 agonist sotigalimab (APX005M) in addition to pembrolizumab (Keytruda) elicited immunologic changes that yielded positive clinical responses in patients with unresectable stage III or IV metastatic melanoma, according to phase 1/2 findings (NCT02706353) presented during the 2022 AACR Annual Meeting.

Evaxion Biotech Adopts Personalis Immune Profiling Platform for Melanoma Immunotherapy Trial

NEW YORK – Personalized cancer therapy firm Evaxion Biotech and cancer genomics firm Personalis said on Tuesday that they will use Personalis’ immune profiling platform in a Phase IIb trial evaluating the efficacy and safety of Evaxion’s neoepitope-targeting therapy EVX-01, in combination with Merck’s Keytruda (pembrolizumab), for advanced melanoma patients.

Dr. Kirkwood on the Use of Ipilimumab/Nivolumab in Melanoma With Brain Metastases

John M. Kirkwood, MD, director, the Melanoma Center, UPMC Hillman Cancer Center, professor of Medicine, Dermatology, and Clinical and Translational Ccience, the University of Pittsburgh School of Medicine, the Clinical and Translational Science Institute, the University of Pittsburgh, discusses the utilization of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with melanoma with brain metastases.

Researchers Propose Novel Methodology for Computer-Aided Diagnostic System in Melanoma

In cancer care, early diagnosis and treatment is crucial for the best possible outcomes. This is certainly true in skin cancer, which is the most common type of cancer in the United States and one of the fastest growing causes of death. A recent study published in Scientific Reports explored a novel deep learning-based, automatic system for skin lesion segmentation to aid in early melanoma diagnosis.

Immune-Related Adverse Events With Immune Checkpoint Inhibitor Treatment for Melanoma in Older White Patients

In a population-based cohort study reported in JAMA Network Open, Schonfeld et al identified the incidence of immune-related adverse events among White patients aged >= 65 years with newly diagnosed melanoma treated with immune checkpoint inhibitors. They compared risk of these adverse events with that among patients who did not receive immune checkpoint inhibitors.
Study Details

MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors for Patients with Melanoma

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announced today the initiation of a Phase 2a clinical trial1 sponsored by AP-HP2, evaluating MaaT013, MaaT Pharma’s lead Microbiome Ecosystem Therapy candidate, in combination with immune checkpoint inhibitors (ICI), ipilimumab (Yervoy®) and nivolumab (Opdivo®), which are standard first line treatments for patients with metastatic melanoma.

Roswell Park Explores Stress Receptors as Possible Immune Checkpoint, Suggesting Role for Beta-Blockers in Cancer Treatment

Combining a beta-blocker with the cancer immunotherapy drug pembrolizumab could be a promising new treatment option for many hard-to-treat solid-tumor cancers. At the American Association for Cancer Research (AACR) Annual Meeting 2022, researchers from Roswell Park will report on a study of this approach in patients with advanced melanoma.

“Melanoma in Mexicans has increased by 500% in 30 years, we must study the cause”

Few know that melanoma, or melanoma, which is most common in Mexico, is not caused by ultraviolet radiation, as it does in people of white skin and European genetic ancestry. However, the world’s largest cancer research centers have no priority for studying what might be the specific genetic mutations of Mexicans and Latin Americans that generate cancer cells in the skin.

Opdivo Plus Experimental Drug Combo Fails to Improve Survival, Response Rates in Patients With Advanced Melanoma

The use of bempegaldesleukin and Opdivo failed to meet its goal of significantly improving progression-free survival and responses to treatment, compared with Opdivo alone in patients with previously untreated unresectable or metastatic melanoma, according to data from an initial analysis of the phase 3 PIVOT IO-001 study.

Melanoma: A rising aggressive type of skin cancer

As we commemorated the World Cancer Day on February 4 as a day for raising awareness to early detection, prevention and treatment of cancer, it is also a time for everyone to reflect on how far we have advanced in the management of many types of cancers and appreciate that cancer is no longer the end of life or hope in Rwanda. 

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma

The efficacy seen with ripretinib (Qinlock) in patients with KIT-mutated melanoma was higher than has been previously reported, according to Filip Janku, MD, PhD. Furthermore, the switch-control tyrosine kinase inhibitor (TKI) has elicited durable responses, even in patients who were heavily pretreated, making the drug a powerful tool for this patient population.

Dr. Tawbi on the Safety Profile of Relatlimab Plus Nivolumab in Advanced Melanoma

Hussein A. Tawbi, MD, PhD, deputy chair, professor, director of melanoma clinical research and early drug development, director of personalized cancer therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of relatlimab plus nivolumab (Opdivo) in advanced melanoma.

Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology

Ultimovacs ASA (“Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in Frontiers in Immunology of its positive long-term Overall Survival (OS) data from the Phase I trial evaluating the Company’s universal cancer vaccine, UV1, in combination with checkpoint inhibitor ipilimumab in patients with metastatic malignant melanoma.

31-Gene Expression Profile Test Improves Risk Assessment in Cutaneous Melanoma

Combining the 31-gene expression profile (GEP) test with current American Joint Committee on Cancer (AJCC) staging guidelines may improve risk assessment in patients with cutaneous melanoma, as well as determine which patients could be candidates for more intense follow-up, according to data from a multicenter, prospective cohort study published in JCO Precision Oncology.1